166 related articles for article (PubMed ID: 31712777)
41. Recurrent involvement of heterochromatic regions in multiple myeloma-a multicolor FISH study.
Lange K; Gadzicki D; Schlegelberger B; Göhring G
Leuk Res; 2010 Aug; 34(8):1002-6. PubMed ID: 20022374
[TBL] [Abstract][Full Text] [Related]
42. Review of Bayesian statistical analysis methods for cytogenetic radiation biodosimetry, with a practical example.
Ainsbury EA; Vinnikov VA; Puig P; Higueras M; Maznyk NA; Lloyd DC; Rothkamm K
Radiat Prot Dosimetry; 2014 Dec; 162(3):185-96. PubMed ID: 24282320
[TBL] [Abstract][Full Text] [Related]
43. Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma.
Ledergor G; Weiner A; Zada M; Wang SY; Cohen YC; Gatt ME; Snir N; Magen H; Koren-Michowitz M; Herzog-Tzarfati K; Keren-Shaul H; Bornstein C; Rotkopf R; Yofe I; David E; Yellapantula V; Kay S; Salai M; Ben Yehuda D; Nagler A; Shvidel L; Orr-Urtreger A; Halpern KB; Itzkovitz S; Landgren O; San-Miguel J; Paiva B; Keats JJ; Papaemmanuil E; Avivi I; Barbash GI; Tanay A; Amit I
Nat Med; 2018 Dec; 24(12):1867-1876. PubMed ID: 30523328
[TBL] [Abstract][Full Text] [Related]
44. Smoldering Myeloma Treatment: Who, What, and When.
Mejia Saldarriaga M; Rossi A
Cancer J; 2021 May-Jun 01; 27(3):185-189. PubMed ID: 34549905
[TBL] [Abstract][Full Text] [Related]
45. Cytogenetic analysis of tumor clonality.
Teixeira MR; Heim S
Adv Cancer Res; 2011; 112():127-49. PubMed ID: 21925303
[TBL] [Abstract][Full Text] [Related]
46. Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma.
Binder M; Rajkumar SV; Ketterling RP; Dispenzieri A; Lacy MQ; Gertz MA; Buadi FK; Hayman SR; Hwa YL; Zeldenrust SR; Lust JA; Russell SJ; Leung N; Kapoor P; Go RS; Gonsalves WI; Kyle RA; Kumar SK
Blood Cancer J; 2016 Mar; 6(3):e401. PubMed ID: 26967818
[TBL] [Abstract][Full Text] [Related]
47. Prognostic impact of cytogenetic aberrations in patients with multiple myeloma or monoclonal gammopathy of unknown significance.
Schilling G; Dierlamm J; Hossfeld DK
Hematol Oncol; 2005; 23(3-4):102-7. PubMed ID: 16342296
[TBL] [Abstract][Full Text] [Related]
48. [Cytogenetic characteristics of patients with multiple myeloma in China: analysis of 100 case].
Deng SH; Xu Y; Wang YF; Mai YJ; Liu XP; Zhao YZ; Zou DH; Wang Y; Qiu LG
Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(24):1685-8. PubMed ID: 17825148
[TBL] [Abstract][Full Text] [Related]
49. HUMAN KARYOTYPE ANALYSIS IN DIAGNOSIS VERIFICATION.
Gayner TA; Matveeva VG; Karimov OG; Shorina AR; Rubtsov NB; Karamysheva TV
Tsitologiia; 2016; 58(6):482-7. PubMed ID: 30192121
[TBL] [Abstract][Full Text] [Related]
50. Chromosomal aberrations of multiple myeloma in Chinese patients at diagnosis: a study by combined G-banding and multicolor spectral karyotyping.
Ng MH; Wong N; Lau TT; Tsang KS; Cheng SH; Chan NP; Tang SH; Lei KI; Leung Y
Oncol Rep; 2003; 10(3):587-91. PubMed ID: 12684628
[TBL] [Abstract][Full Text] [Related]
51. Relapse and cytogenetic evolution in myeloid neoplasms.
Ertz-Archambault N; Kelemen K
Panminerva Med; 2017 Dec; 59(4):308-319. PubMed ID: 29144072
[TBL] [Abstract][Full Text] [Related]
52. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).
Landgren CO; Chari A; Cohen YC; Spencer A; Voorhees P; Estell JA; Sandhu I; Jenner MW; Williams C; Cavo M; van de Donk NWCJ; Beksac M; Moreau P; Goldschmidt H; Kuppens S; Bandekar R; Clemens PL; Neff T; Heuck C; Qi M; Hofmeister CC
Leukemia; 2020 Jul; 34(7):1840-1852. PubMed ID: 32024950
[TBL] [Abstract][Full Text] [Related]
53. Pseudohyperphosphatemia in a patient with incidentally identified progression of smoldering myeloma.
Francis ER; Chen F; Kidacki M; Miller R; Alkhasoneh M; Talamo G; Straub M; Klinefelter K; Kodali N; Zhu Y
Clin Chim Acta; 2018 Dec; 487():306-308. PubMed ID: 30315756
[TBL] [Abstract][Full Text] [Related]
54. Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review.
Maura F; Bolli N; Rustad EH; Hultcrantz M; Munshi N; Landgren O
JAMA Oncol; 2020 Mar; 6(3):425-432. PubMed ID: 31830214
[TBL] [Abstract][Full Text] [Related]
55. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells.
López-Corral L; Gutiérrez NC; Vidriales MB; Mateos MV; Rasillo A; García-Sanz R; Paiva B; San Miguel JF
Clin Cancer Res; 2011 Apr; 17(7):1692-700. PubMed ID: 21325290
[TBL] [Abstract][Full Text] [Related]
56. Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease.
Isola I; Brasó-Maristany F; Moreno DF; Mena MP; Oliver-Calders A; Paré L; Rodríguez-Lobato LG; Martin-Antonio B; Cibeira MT; Bladé J; Rosiñol L; Prat A; Lozano E; Fernández de Larrea C
Front Immunol; 2021; 12():792609. PubMed ID: 34880879
[TBL] [Abstract][Full Text] [Related]
57. Chromosome Recognition.
Wan TS; Hui EK; Ng MH
Methods Mol Biol; 2017; 1541():67-74. PubMed ID: 27910015
[TBL] [Abstract][Full Text] [Related]
58. Metaphase harvest and cytogenetic analysis of malignant hematological specimens.
Dal Cin P; McLaughlin C
Curr Protoc Hum Genet; 2012 Apr; Chapter 10():Unit 10.2.1-15. PubMed ID: 22470141
[TBL] [Abstract][Full Text] [Related]
59. Diagnosis and Management of Monoclonal Gammopathy and Smoldering Multiple Myeloma.
Schmidt T; Callander N
J Natl Compr Canc Netw; 2020 Dec; 18(12):1720-1729. PubMed ID: 33347744
[TBL] [Abstract][Full Text] [Related]
60. Cytogenetics in myelodysplastic syndromes.
Ohyashiki K; Kodama A; Ohyashiki JH
Methods Mol Biol; 2011; 730():79-88. PubMed ID: 21431635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
